Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
This year's edition of the EvaluatePharma World Preview arrives at a time when the global economy is reeling. The impact of COVID-19 has so far wiped $7.85bn off forecasts for biopharma sales in 2020, with the top 15 companies bearing 60% of that loss.
However, despite dampening sales in the near-term, demand for innovative and effective therapies continues to drive long-term growth. Prescription drug sales are forecast to grow 3.7% in 2020 to $904bn, and reach almost $1.4 trillion in 2026, with orphan drugs and oncology products continuing to be high-performing segments.